Detalles de la búsqueda
1.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
N Engl J Med;
389(20): 1862-1876, 2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37966285
2.
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.
Alzheimers Dement;
20(4): 2698-2706, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38400532
3.
Standard and reference-based conditional mean imputation.
Pharm Stat;
21(6): 1246-1257, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35587109
4.
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
Blood;
131(9): 955-962, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29255066
5.
Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach.
Alzheimers Dement;
16(5): 797-803, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32270600
6.
Rejoinder to the letter: "Standard and reference-based conditional mean imputation: Regulators and trial statisticians be aware!"
Pharm Stat;
2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38631676
7.
A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease.
Stat Med;
37(21): 3047-3055, 2018 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29761523
8.
Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects.
Pharm Stat;
17(2): 169-181, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29282862
9.
Genetic markers of bevacizumab-induced hypertension.
Angiogenesis;
17(3): 685-94, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24558090
10.
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.
Angiogenesis;
17(4): 909-20, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25012543
11.
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
Lancet Oncol;
13(7): 724-33, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22608783
12.
Comparing ARIA-E severity scales and effects of treatment management thresholds.
Alzheimers Dement (Amst);
14(1): e12376, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36474747
13.
Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease.
Alzheimers Dement (N Y);
8(1): e12286, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35415211
14.
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
Alzheimers Dement (N Y);
8(1): e12306, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35676943
15.
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Alzheimers Dement (Amst);
14(1): e12367, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36348972
16.
A statistician's perspective on biomarkers in drug development.
Pharm Stat;
10(6): 494-507, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22162336
17.
Classification, Prediction, and Concordance of Cognitive and Functional Progression in Patients with Mild Cognitive Impairment in the United States: A Latent Class Analysis.
J Alzheimers Dis;
82(4): 1667-1682, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34219723
18.
Changes in transcriptome after in vivo exposure to ionising radiation reveal a highly specialised liver response.
Int J Radiat Biol;
85(8): 656-71, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19637078
19.
Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.
Curr Med Res Opin;
35(3): 535-542, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30296185
20.
Gantenerumab reduces amyloid-ß plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
Alzheimers Res Ther;
11(1): 101, 2019 12 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31831056